Adeno-Associated Viral Vectors Global Market Report 2024

The adeno-associated viral vectors market size has grown rapidly in recent years. It will grow from $2.29 billion in 2023 to $2.69 billion in 2024 at a compound annual growth rate (CAGR) of 17.6%. The growth during the historical period can be attributed to several factors, including vaccine development, increased funding and investment, collaborations between academia and industry, expansion of clinical trials, and public awareness and advocacy efforts.

The adeno-associated viral vectors market size is expected to see rapid growth in the next few years. It will grow to $5.17 billion in 2028 at a compound annual growth rate (CAGR) of 17.7%. In the forecast period, growth can be attributed to expanding therapeutic applications, increasing prevalence of genetic disorders and neurological disorders, regulatory approvals and support, and cost reductions in production. Major trends expected include advancements in gene therapy, technological innovations, scalable manufacturing processes, collaborations and investments, and overall technological advancements in the field.

The adeno-associated viral vectors market is poised for growth due to the increasing prevalence of genetic disorders. Genetic disorders arise from abnormalities in an individual's DNA, leading to physical or developmental issues. Factors such as improved diagnostic techniques, greater awareness, advanced reproductive age, environmental influences, and genetic drift contribute to the rising prevalence of genetic disorders. Adeno-associated viral vectors play a crucial role in gene therapy for these disorders by delivering corrective genes into target cells, potentially treating conditions such as muscular dystrophy or cystic fibrosis. For example, the World Health Organization (WHO) reported in February 2023 that congenital diseases caused approximately 240,000 infant deaths globally within 28 days of birth annually, with an additional 170,000 deaths in children aged 1 month to 5 years, highlighting the driving force behind the adeno-associated viral vectors market.

Key players in the adeno-associated viral vectors market are emphasizing off-the-shelf availability of replication-capsid plasmids to enhance their competitiveness. Rep/Cap plasmids, widely used in gene therapy for adeno-associated virus (AAV) vector production, are readily accessible from multiple commercial suppliers catering to molecular biology research requirements. For instance, Charles River Laboratories International Inc. introduced an off-the-shelf replication-capsid plasmid range in January 2024, streamlining AAV-based gene therapy initiatives. This expansion of their product portfolio complements existing lentiviral packaging and AAV Helper plasmid offerings, reducing manufacturing efforts by up to 66%. These ready-to-use plasmids undergo batch production with detailed documentation, complying with CMC guidelines and accompanied by Certification of Analysis (COA) to facilitate IND and Clinical Trial Application (CTA) submissions.

In June 2021, Charles River Laboratories International Inc. acquired Vigene Biosciences Inc. for $292.5 million to strengthen its capabilities in the high-growth cell and gene therapy contract development and manufacturing organization (CDMO) sector. Vigene Biosciences Inc. is a US-based CDMO company specializing in solutions for cell and gene therapy, including adeno-associated viral vectors.

Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics.

North America was the largest region in the adeno-associated viral vectors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the adeno-associated viral vectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Adeno-associated viral vectors (AAV) are small, non-pathogenic viruses extensively used in gene therapy to deliver therapeutic genes into target cells, offering potential treatments for genetic disorders, cancers, and various diseases. Their safety profile and efficient infection of both dividing and non-dividing cells make them valuable tools in biomedical research and clinical applications.

The main types of AAV therapy are gene augmentation, immunotherapy, and others. Gene augmentation involves introducing a functional gene to replace or supplement a defective or missing gene in a patient's cells. This therapy can be delivered through ex vivo or in vivo methods, targeting therapeutic areas such as genetic disorders, hematological disorders, infectious diseases, metabolic disorders, ophthalmic disorders, muscle disorders, neurological disorders, and more. The scale of operation ranges from preclinical and clinical stages to commercial applications, applied in gene therapy, cell therapy, and vaccines.

The adeno-associated viral vectors market research report is one of a series of new reports that provides adeno-associated viral vectors market statistics, including adeno-associated viral vectors industry global market size, regional shares, competitors with a adeno-associated viral vectors market share, detailed adeno-associated viral vectors market segments, market trends and opportunities, and any further data you may need to thrive in the adeno-associated viral vectors industry. This adeno-associated viral vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adeno-associated viral vectors market consists of sales of recombinant adeno-associated viral vectors (AAV), serotype-specific adeno-associated viral vectors (AAV), and custom adeno-associated viral vectors (AAV). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.